Skip to main content

News

Lorem ipsum dolor sit amet, sed do eiusmod tempor incididunt et dolore magna aliqua.

Thaerapy BV and Resyca BV announce exclusive licence agreement for Soft Mist Inhaler technology

Stevanato Group collaborates with Resyca ® to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products

10 August, 2022

The potential of nasal sprays for vaccination

17 November, 2021

Pharmaceutical scientist Imco Sibum about our soft mist inhaler

29 September, 2021

First pharmaceutical customer on the soft mist inhaler (SMI) platform

09 August, 2021

Resyca brand and website

03 August, 2021

Successful clinical trial in COVID with Heparin in Pulmospray

01 February, 2021

Joint venture Recipharm and Medspray